Evolution and Genotypic Characteristics of Small Cell Lung Cancer Transformation in Non-Small Cell Lung Carcinomas

Abstract Objective Small cell lung cancer (SCLC) transformation had previously been reported mainly in epidermal growth factor receptor (EGFR) mutant adenocarcinoma. However, the underlying genomic profile remains unclear. Our study aim to find the evolution and genotypic characteristic of SCLC transformation. Patients and methods Thirty-one SCLC transformation patients who were initially diagnosed as Non-Small Cell Lung Cancer (NSCLC) patients were included. Whole exome sequencing (WES) of both primary and transformed re-biopsy lesions was conducted on 12 patients. Clinical characteristics were analyzed using R software (v.3.6.1). Results Our study included 31 patients, of whom, three had lung squamous cell carcinoma. Six patients did not carry EGFR mutations. Thirty patients received chemotherapy for SCLCs. The disease control rate (DCR) was 96.7%, and the median progression-free survival (PFS) was 4.03 months. The median time to transformation was 33.07 months, and the median overall survival (OS) was 62.08 months. Somatic mutation analysis showed that besides TP53, RB1, and EGFR, there was a high occurrence of mutations to CSMD3 and ADAMTS19, especially in the EGFR-wild type (EGFR-wt) group. Concerning mutational signature, the EGFR-mutant (EFFR-mut) transformed group favored an APOBEC (apolipoprotein B mRNA editing catalytic polypeptide-like)-associated mutation pattern (P = 0.16). DNA Damage Repair (DDR)-related signatures were significantly enriched in the EGFR-wt transformed group (P = 0.034). Additionally, clonal evolution analysis revealed that all patients had the same main trunk genes in the phylogenetic tree. Transformed SCLCs are not sensitive to immunotherapy, possibly due to increased tumor heterogeneity. Conclusion Our results indicated that the EGFR-wt patients could also transform to SCLCs, but they have different genetic features with EGFR-mut patients. SCLC-transformed patients respond to classical chemotherapy and have a better prognosis than those with classical SCLCs.